Patrick A. Baeuerle, Ph.D.
Dr. Patrick A. Baeuerle is the co-founder of six MPM oncology portfolio companies; Harpoon Therapeutics, iOmx Therapeutics, Maverick Therapeutics, TCR² Therapeutics, Werewolf Therapeutics and Cullinan Oncology, where he is the CSO of Biologics. Patrick serves on the board of directors of Harpoon, TCR2 and Werewolf, on the scientific advisory boards of Amphivena Therapeutics, ElevateBio, Harpoon, iOmx, Maverick, and TCR2, and on the investment committee of MPM’s oncology-only crossover investment strategy (both public and private equities).
Prior to joining MPM, Patrick served as Vice President of Research and General Manager of Amgen Research Munich GmbH, where he was responsible for the development of BiTE antibody Blincyto®, which was approved by the U.S. FDA in 2014 in less than three months as a therapy for relapsed/refractory acute lymphoblastic leukemia. He has also served as CSO for Micromet, and earlier headed small-molecule drug discovery at Tularik, a publicly traded biotechnology company also acquired by Amgen. Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick is the recipient of the European Molecular Biology Laboratory’s 2019 Lennart Philipson Award in recognition of his many contributions to the development of cancer immunotherapies. To date, he has published 240 PubMed-listed papers that have been cited more than 69,800 times. He has a Hirsh index of 126 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997).
Patrick holds a Ph.D. in Biology from the University of Munich and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at the University of Munich.